CY1119901T1 - Αναστολεις απομεθυλασων ιστονων - Google Patents

Αναστολεις απομεθυλασων ιστονων

Info

Publication number
CY1119901T1
CY1119901T1 CY20181100164T CY181100164T CY1119901T1 CY 1119901 T1 CY1119901 T1 CY 1119901T1 CY 20181100164 T CY20181100164 T CY 20181100164T CY 181100164 T CY181100164 T CY 181100164T CY 1119901 T1 CY1119901 T1 CY 1119901T1
Authority
CY
Cyprus
Prior art keywords
cancer
compounds
compositions
useful
treatment
Prior art date
Application number
CY20181100164T
Other languages
Greek (el)
English (en)
Inventor
Toufike Kanouni
Jeffery Alan Stafford
James Marvin Veal
Michael Brennan Wallace
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of CY1119901T1 publication Critical patent/CY1119901T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CY20181100164T 2012-12-19 2018-02-09 Αναστολεις απομεθυλασων ιστονων CY1119901T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739521P 2012-12-19 2012-12-19
US201361792930P 2013-03-15 2013-03-15
PCT/US2013/076666 WO2014100463A1 (en) 2012-12-19 2013-12-19 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
CY1119901T1 true CY1119901T1 (el) 2018-06-27

Family

ID=50931614

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100164T CY1119901T1 (el) 2012-12-19 2018-02-09 Αναστολεις απομεθυλασων ιστονων

Country Status (17)

Country Link
US (4) US8969343B2 (OSRAM)
EP (1) EP2934145B1 (OSRAM)
JP (1) JP6256772B2 (OSRAM)
AU (1) AU2013361255B2 (OSRAM)
CA (1) CA2895355A1 (OSRAM)
CY (1) CY1119901T1 (OSRAM)
DK (1) DK2934145T3 (OSRAM)
ES (1) ES2658597T3 (OSRAM)
HR (1) HRP20180067T1 (OSRAM)
HU (1) HUE037312T2 (OSRAM)
LT (1) LT2934145T (OSRAM)
PL (1) PL2934145T3 (OSRAM)
PT (1) PT2934145T (OSRAM)
RS (1) RS56821B1 (OSRAM)
SI (1) SI2934145T1 (OSRAM)
SM (1) SMT201800070T1 (OSRAM)
WO (1) WO2014100463A1 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208043B2 (en) 2012-08-22 2019-02-19 Cornell University Methods for inhibiting fascin
HRP20170358T1 (hr) 2012-10-02 2017-04-21 Gilead Sciences, Inc. Inhibitori histonskih demetilaza
PL2934145T3 (pl) 2012-12-19 2018-04-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy histonowej
KR20150100814A (ko) 2012-12-21 2015-09-02 콴티셀 파마슈티컬스, 인크. 히스톤 데메틸라제 억제제
ES2670864T3 (es) 2013-02-27 2018-06-01 Gilead Sciences, Inc. Inhibidores de histonas desmetilasas
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
JP6691869B2 (ja) 2014-02-20 2020-05-13 コーネル ユニヴァーシティー ファシンを阻害するための化合物及び方法
US10385047B2 (en) 2014-06-25 2019-08-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
EP3194387B1 (en) 2014-09-17 2019-07-31 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN107205391A (zh) 2014-09-17 2017-09-26 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6883913B2 (ja) * 2015-12-28 2021-06-09 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
CN105601555B (zh) * 2016-03-14 2018-07-31 苏州大学 一种制备硝基吲哚衍生物的方法
WO2017161012A1 (en) * 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
EP4234691A3 (en) 2016-10-14 2023-10-18 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
EP3535242B1 (en) * 2016-10-20 2024-01-24 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Dna primase and gyrase inhibitors
AR110768A1 (es) 2017-01-31 2019-05-02 Gilead Sciences Inc Formas cristalinas de tenofovir alafenamida
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
WO2018149986A1 (en) * 2017-02-16 2018-08-23 Oryzon Genomics, S.A. 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司(Us) 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
US20230303599A1 (en) 2020-08-07 2023-09-28 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2023386923A1 (en) 2022-11-21 2025-05-15 Nippon Shinyaku Co., Ltd. Compound serving as ddr1 kinase inhibitor, and medicine
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593349B2 (en) * 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
MXPA05001807A (es) * 2002-09-05 2005-04-19 Aventis Pharma Sa Nuevos derivados de aminoindazol utilizados como medicamentos y composiciones farmaceuticas que los contienen.
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
FR2882361A1 (fr) * 2005-02-22 2006-08-25 Aventis Pharma Sa Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation
AU2007275653B2 (en) * 2006-07-20 2010-12-23 Amgen Inc. Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine
PH12013501594A1 (en) * 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
AU2009320683B2 (en) 2008-11-28 2012-07-19 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換6,5−縮合二環式ヘテロアリール化合物
PL2934145T3 (pl) 2012-12-19 2018-04-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy histonowej

Also Published As

Publication number Publication date
WO2014100463A1 (en) 2014-06-26
RS56821B1 (sr) 2018-04-30
CA2895355A1 (en) 2014-06-26
SMT201800070T1 (it) 2018-03-08
EP2934145B1 (en) 2017-11-15
JP6256772B2 (ja) 2018-01-10
AU2013361255B2 (en) 2017-01-05
LT2934145T (lt) 2018-02-26
SI2934145T1 (en) 2018-03-30
EP2934145A1 (en) 2015-10-28
JP2016503799A (ja) 2016-02-08
HUE037312T2 (hu) 2018-08-28
PL2934145T3 (pl) 2018-04-30
US8969343B2 (en) 2015-03-03
ES2658597T3 (es) 2018-03-12
PT2934145T (pt) 2018-02-13
US10336727B2 (en) 2019-07-02
US9617242B2 (en) 2017-04-11
EP2934145A4 (en) 2016-06-29
US20140171432A1 (en) 2014-06-19
AU2013361255A1 (en) 2015-07-09
US20180305336A1 (en) 2018-10-25
US10040779B2 (en) 2018-08-07
DK2934145T3 (en) 2018-02-05
HRP20180067T1 (hr) 2018-02-23
US20160060247A1 (en) 2016-03-03
US20170174656A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123906T1 (el) Αναστολεις απομεθυλασης ιστονης
CY1119476T1 (el) Αναστολεις της απομεθυλασης ιστονης
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1122886T1 (el) Αναστολεις βρωμοεπικρατειων
CY1123626T1 (el) Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1119714T1 (el) Ενωσεις αναστολεων
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1121763T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
MX376047B (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
EA201591145A1 (ru) Ингибиторы гистондеметилазы